GT Biopharma, Inc. (GTBP)
GTBP Stock Price Chart
Explore GT Biopharma, Inc. interactive price chart. Choose custom timeframes to analyze GTBP price movements and trends.
GTBP Company Profile
Discover essential business fundamentals and corporate details for GT Biopharma, Inc. (GTBP) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
27 Mar 2018
Employees
1.00
Website
https://www.gtbiopharma.comCEO
Michael Martin Breen
Description
GT Biopharma, Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and bringing to market novel immuno-oncology treatments. Their innovative approach centers on a proprietary technology platform called Tri-specific Killer Engager (TriKE) fusion proteins, which are designed to harness the body's immune cells. Central to their pipeline is GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate currently undergoing Phase I/II clinical trials. This therapeutic candidate is being evaluated for its potential in treating myelodysplastic syndromes, acute myeloid leukemia that has relapsed or proven refractory to prior treatments, advanced systemic mastocytosis, and other malignancies expressing CD33. The company's research also includes GTB-3650, which is in preclinical development targeting CD33 on myeloid leukemias, and GTB-5550, another preclinical asset aimed at solid tumors that are positive for B7-H3. GT Biopharma has forged key collaborations, including a co-development agreement with Altor BioScience Corporation for the clinical advancement of a 161533 TriKE fusion protein for various cancer indications. Furthermore, they maintain a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies utilizing their TriKE technology. Founded in 1965, the company previously operated as OXIS International, Inc. before rebranding to GT Biopharma, Inc. in July 2017. Its corporate operations are based in Brisbane, California.
GTBP Financial Timeline
Browse a chronological timeline of GT Biopharma, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 Aug 2026
EPS estimate is -$0.08.
Earnings released on 15 May 2026
EPS came in at -$0.11 falling short of the estimated -$0.08 by -37.50%.
Earnings released on 2 Mar 2026
EPS came in at -$2.22 falling short of the estimated -$0.22 by -909.09%.
Earnings released on 14 Nov 2025
EPS came in at -$0.83 falling short of the estimated -$0.38 by -118.42%.
Earnings released on 14 Aug 2025
EPS came in at -$0.55 surpassing the estimated -$0.68 by +19.12%.
Earnings released on 15 May 2025
EPS came in at -$0.76 falling short of the estimated -$0.64 by -18.75%.
Earnings released on 21 Feb 2025
EPS came in at -$1.66 falling short of the estimated -$1.55 by -7.10%.
Earnings released on 14 Nov 2024
EPS came in at -$1.53 surpassing the estimated -$2.70 by +43.33%.
Earnings released on 14 Aug 2024
EPS came in at -$2.24 surpassing the estimated -$2.70 by +17.04%.
Earnings released on 15 May 2024
EPS came in at -$2.12 surpassing the estimated -$2.70 by +21.48%.
Earnings released on 4 Apr 2024
EPS came in at -$2.19 surpassing the estimated -$2.70 by +18.89%.
Stock split effective on 5 Feb 2024
Shares were split 1 : 30 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 1 Nov 2023
EPS came in at -$1.80 surpassing the estimated -$3.00 by +40.00%.
Earnings released on 7 Aug 2023
EPS came in at -$2.70 surpassing the estimated -$3.00 by +10.00%.
Earnings released on 15 May 2023
EPS came in at -$2.40 surpassing the estimated -$4.80 by +50.00%.
Earnings released on 30 Mar 2023
EPS came in at -$5.41 falling short of the estimated -$0.17 by -3.08k%.
Earnings released on 31 Oct 2022
EPS came in at -$6.61 falling short of the estimated -$3.30 by -100.30%.
Earnings released on 11 Aug 2022
EPS came in at -$3.00 surpassing the estimated -$5.41 by +44.55%.
Earnings released on 16 May 2022
EPS came in at -$5.11 surpassing the estimated -$6.91 by +26.05%.
Earnings released on 28 Mar 2022
EPS came in at -$15.62 falling short of the estimated -$6.31 by -147.54%.
Earnings released on 10 Nov 2021
EPS came in at -$5.11 surpassing the estimated -$6.31 by +19.02%.
Earnings released on 23 Aug 2021
EPS came in at -$4.50 surpassing the estimated -$8.41 by +46.49%.
GTBP Stock Performance
Access detailed GTBP performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
